The tension between the Federal Trade Commission (FTC) and pharmacy benefit managers (PBMs) has escalated significantly. Last week, the FTC filed a lawsuit against the three largest PBMs in the nation – CVS Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s Optum Rx. The lawsuit alleges that these PBMs, along with their secretive group purchasing organizations, have created a system of rebates that has led to a substantial increase in the price of insulin, as reported by my colleague, Ed Silverman.
In response to the lawsuit, the accused PBMs vehemently denied the allegations and shifted the blame onto insulin manufacturers. However, Rahul Rao, deputy director of the FTC’s Bureau of Competition, emphasized that the major insulin manufacturers should be aware that their participation in such practices could raise serious concerns.
The lawsuit has sparked a heated debate within the healthcare industry, with stakeholders closely monitoring the developments. The outcome of this legal battle could have far-reaching implications for the pricing and accessibility of essential medications like insulin.
Unfortunately, access to the full article is restricted to STAT+ subscribers only. To unlock this exclusive content and gain access to in-depth analysis, newsletters, premium events, and news alerts, interested readers are encouraged to subscribe to STAT+.
For those who are already subscribers, simply log in to view the complete article. Subscribers can stay informed about the latest updates and insights in the healthcare sector by accessing the full range of articles and resources available on STAT+.
Stay tuned for further updates on the FTC’s lawsuit against the Big 3 PBMs and the impact it may have on the healthcare landscape. Subscribe to STAT+ today to stay ahead of the curve and deepen your understanding of the evolving dynamics in the healthcare industry.
